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The ATP-dependent ClpQY protease system in Plasmodium falciparum is a prokaryotic machinery in the parasite. In the present
study, we have identiﬁed the complete ClpQY system in P. falciparum and elucidated its functional importance in survival and
growth of asexual stage parasites. We characterized the interaction of P. falciparum ClpQ protease (PfClpQ) and PfClpY ATPase
components, and showed that a short stretch of residues at the C terminus of PfClpY has an important role in this interaction;
a synthetic peptide corresponding to this region antagonizes this interaction and interferes with the functioning of this
machinery in the parasite. Disruption of ClpQY function by this peptide caused hindrance in the parasite growth and maturation
of asexual stages of parasites. Detailed analyses of cellular effects in these parasites showed features of apoptosis-like cell
death. The peptide-treated parasites showed mitochondrial dysfunction and loss of mitochondrial membrane potential.
Dysfunctioningofmitochondriainitiatedacascadeofreactionsinparasites,includingactivationofVAD–FMK-bindingproteases
andnucleases,whichresulted inapoptosis-likecelldeath.Theseresultsshowfunctionalimportanceofmitochondrialproteases
in the parasite and involvement of mitochondria in programmed cell death in the malaria parasites.
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Malaria remains a major parasitic disease in the tropical and
sub-tropical countries causing 1–2 million deaths globally
every year.
1,2 The malaria parasite harbors two organelles of
prokaryotic origin, the mitochondrion and the apicoplast. The
metabolic pathways in these organelles are important for
growth cycle and survival of the parasite.
3–5 Characterization
of novel metabolic pathways in these organelles and under-
standing their functional role in parasite growth and survival
may be a key step to design new anti-malarial strategies.
ATP-dependent protease machineries including the eukar-
yotic 26S proteasome and the prokaryotic casenolytic
proteases (Clp) systems are large protein-degradation com-
plexes that have an essential role in cell-cycle regulation.
6,7
The ClpQY machinery is a multimeric ATP-dependent
protease system in prokaryotes that resembles the eukaryotic
26S proteasome; it consists of two stacked hexameric rings of
ClpQ protease that are capped on one of both sides with a
hexamericringofAAA-type ATPase,ClpY.
8TheATPasesact
as chaperons to unfold the substrate proteins, which subse-
quently get degraded by the protease component. Interaction
of protease and ATPase components is essential for proper
functioning of these protease machineries.
8,9
The eukaryotic 26S proteasome machinery is an impor-
tant regulatory system that controls level of key cell-cycle
regulators and transcription factors;
7,10 Inhibition of the 26S
proteasome dysregulates cell processes that leads to
apoptosis of eukaryotic cells.
10–12 The ClpQY machinery
shows mechanistic resemblance with 26S proteasome.
7 The
ClpQY machinery is shown to regulate levels of cell division
inhibitor and to function as an activator of capsular poly-
saccharide synthesis.
13
The P. falciparum genome harbors two Clp protease systems,
ClpQY and ClpAP. We have earlier characterized P. falciparum
ClpQ (PfClpQ) protease and ClpP protease system.
14,15 The
PfClpQ protease is localized in mitochondria whereas PfClpP
is localized in apicoplast, relict plastid in the parasite.
15,16 Our
interest in understanding functional importance of prokaryotic
machineries in the parasite prompted us to assess possible
functional role of the ClpQY machinery in the parasite. In the
present study, we have functionally characterized complete
ClpQY system in P. falciparum. Disruption of ClpQY activity
using a small peptide that interferes with functioning of this
machinery, caused dysregulation of mitochondrial functions,
which in turn activated cascade of reactions leading to
apoptosis-like cell death of the parasite. These results suggest
role of mitochondrial proteases in maintenance of functional
mitochondria and points towards involvement of mitochondria
in apoptosis-like cell death in parasite.
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PfClpQ and PfClpY are expressed in the asexual blood-
stage parasites and form a protein complex. We have
earlier identiﬁed and characterized P. falciparum homolog
of ClpQ protease (PfClpQ).
15 We have now identiﬁed
P. falciparum ClpY orthologue (PfClpY) (See supporting
information) (Figures 1a and b and Supplementary Figure
S1). Real-time quantitative PCR analyses showed that
transcription of pfclpY and pfclpQ start in trophozoite
stages, with maximum transcript levels in late-trophozoite-
and schizont-stage parasites (Supplementary Figure S2).
Western blot analysis using anti-PfClpY antibodies with total
parasite lysates detected PfClpY as a B100kDa protein in
trophozoite and schizont stages (Figure 1c). In addition, a
lower band of B55kDa was also detected that may
represent the processed fragment of PfClpY. The western-
blot analysis using anti-PfClpQ antibodies detected the
pro-PfClpQ (B22kDa) and mature-PfClpQ (B18kDa) in
trophozoite- and schizont- stage parasites with maximum
expression in schizont stage. These results suggest that both
PfClpQ and PfClpY are expressed in the blood-stage
parasites in the late-trophozoite and schizont stages.
We next carried out co-immunoprecipitation studies to
ascertain that the PfClpQ and PfClpY form a protein complex
in the parasite. Western-blot analysis of immunoprecipitated
complex showed that the PfClpQ gets co-immunoprecipitated
with PfClpY from parasite lysate (Figure 1d). The PfClpQ was
not detected in eluates from control reactions with pre-
immune sera or with non-speciﬁc antibodies in place of anti-
PfClpY antibodies. These experiments suggest that the ClpQ
and ClpY are present in the same protein complex in the
parasite; detailed in vitro and yeast two-hybrid assays were
carried out, as described below, to assess if these two
proteinsinteractdirectlytoformtheproteincomplexasincase
of other organisms.
6–8
PfClpY interacts with PfClpQ through its C terminus to
form a protein complex. To ascertain the direct interaction
of PfClpQ and PfClpY and to decipher role of C-terminal
region of PfClpY in this interaction, we carried out different
protein–protein binding assays using recombinant proteins,
as well as by yeast-two-hybrid assays. In an in vitro solution-
binding assay, PfClpQ formed a protein complex with PfClpY
that was pulled down by anti-PfClpY antibodies (Figure 2a);
however PfClpQ did not form a protein complex in control
experiments where PfClpY was replaced with another
recombinant protein, PfMSP119. Next, we also carried out
in vitro solid-phase interaction studies using recombinant
PfClpY and PfClpQ to ascertain their interaction. The PfClpQ
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Figure 1 PfClpQ and PfClpY are expressed in the asexual-stage parasites and form a protein complex in the parasite. (a) Schematic domain structure of PfClpY
(GeneID PFI0355c)showinglocation of N, I and C domains,respective amino-acidpositionsand walkerA andB domainsare also indicated.(b) Schematicrepresentationof
structure of PfClpQ showing location of pro-domain and mature protease. The locations of conserved residues of active site triad are also marked. (c) Western blot analyses
of total lysates of equal number of synchronized parasites at ring (8–10h post invasion (hpi)), trophozoite (30–32hpi) and schizont (42–45hpi) stages with antibodies against
thePfClpQand PfClpYshowingexpression of both theproteinsin trophozoite-schizontstages. Anti-histidine rich protein-II(HRPII) antibodieswereusedto probea blot run in
parallel to show equal loading in each well. (d) Co-immunoprecipitation of PfClpQ and PfClpY from parasite lysate using anti-PfClpY antibodies; PfClpQ protein was
detected in the immunoprecipitated protein complex by western blot analysis. Immunoprecipitation reactions using non-speciﬁc antibodies or no antibodies were used as
controls
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Cell Death and Diseaseshowed binding with the PfClpY in a concentration-
dependent manner. Further, the C-terminal fragment of
PfClpY, PfClpY-C, showed binding with PfClpQ in a similar
manner. However, its truncated version, PfClpY-DC, showed
poor binding with PfClpQ (Figure 2b). Results of yeast two-
hybrid analyses also suggested that PfClpQ and PfClpY
interact with each other and form a protein complex, this
interaction is through C-terminal domain of PfClpY and a
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Figure 2 (a and b) Interaction of PfClpQ with PfClpY and its C-terminal fragments. (a) Solution-binding assays of PfClpQ and PfClpY recombinant proteins followed by
in vitro pulldown of the protein complex using anti-PfClpY antibodies; PfClpQ protein was detected in the pulled down protein complex by western blot analysis. Control
reactions were carried out in the absence of PfClpY protein or replaced with a non-speciﬁc protein (PfMSP-119); in another reaction the anti-ClpY antibodies were replaced
with control antibodies (pre-immune). (b) In vitro solid-phase interaction of PfClpQ with increasing concentration of PfClpY and its C-terminal fragments; protein–protein
interaction was estimated by ELISA using anti-PfClpY antibody. The PfClpY and PfClpY-C showed concentration-dependent interaction with PfClpQ, whereas PfClpY-DC
showed no signiﬁcant binding. (c–e) Interaction of synthetic peptide corresponding to C terminus of PfClpY (FI-peptide) with PfClpQ protein. (c) A solution-binding assay of
PfClpQwithDansyl-labeledFI-peptide(Dansyl-FI),complexformationleadtochangeinﬂuorescenceinthereaction.Fluorescencechange(DF)wasestimatedusingdifferent
concentration of thelabeled peptide.The labeled peptideshowedconcentration-dependentbinding with PfClpQ.(d) Inhibitionof binding of Dansyl-FI and PfClpQ in presence
of increasing concentration of unlabeled FI-peptide. Increasing concentration of unlabeled FI-peptide reduced binding of Dansyl-FI in a concentration-dependent manner.
(e) Global ﬁtting of the sensograms obtained by ﬂowing increasing concentrations (5, 10, 20, 40mM) of FI-peptide for 4mins on PfCIpQ immobilized on the CM5 chip and
dissociationfor 4min under similar ﬂow conditions.Buffer alone was usedas control thatshowedno responsesto PfCIpQ.(f andg) FI-peptideand PfClpYshares thebinding
siteon PfClpQ.(f)PercentagebindingofFI-peptideandPfClpQinasolution-bindingassayinabsenceorpresenceofincreasingconcentrationofPfClpY.PresenceofPfClpY
reducedthebindingofFI-peptideandPfClpQ;a10-foldincreaseinFI-peptideconcentrationrestoredthebindingwithPfClpQ.(g)PercentagebindingofPfClpQandPfClpYin
a ELISA-based assay in absence or presence of increasing concentration of FI peptide
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Cell Death and Diseasestretch of residues in its C terminus has an important role in
this interaction (see Supplementary information; Supplemen-
tary Figure S4; Supplementary Table S2).
C-terminal peptide of PfClpY (FI peptide) binds with
PfClpQ and shares the binding site with PfClpY. To
further study the role of C-terminal region of PfClpY in its
interaction with PfClpQ, we used a 12-amino-acid-long
synthetic peptide (FI-peptide) corresponding to the C
terminus of PfClpY. Binding of PfClpQ with FI-peptide
was studied by ﬂuorescence spectroscopy using dansy-
lated derivative of FI-peptide, Dansyl-FI. The labeled peptide
showed binding with recombinant PfClpQ in a concentration-
dependent manner (Figure 2c). To ascertain speciﬁcity of this
interaction, the interaction of labeled peptide (Dansyl-FI) was
competed with increasing concentrations of unlabeled FI-
peptide. The unlabeled peptide was able to compete
effectively with the labeled peptide and inhibited its binding
with PfClpQ (Figure 2d); however, no inhibition was seen
with a non-speciﬁc peptide.
A surface plasma resonance-based biomolecular-interac-
tion analysis was carried out to quantitatively assess binding
ofClpQand FI-peptide.In thisassay, the recombinantPfClpQ
was used as ligand and FI-peptide was used as analyte. The
assay channel showed typical association and dissociation
curves as compared with the control cells, which show little
ﬂuctuation due to solvent (Figure 2e). However, no difference
in response units was detected when FI-peptide was injected
ineitherblankﬂowcellsorﬂowcellscoatedwithanon-speciﬁc
P. falciparum recombinant protein (MSP-119). Similarly, no
response was observed when a scrambled-FI-peptide was
ﬂowed over immobilized PfClpQ. Therefore, BIACORE
analysis shows speciﬁc binding of PfClpQ with the C-terminal
peptide, FI. The calculated binding constant, Kd, for the ClpQ
and FI-peptide interaction was estimated to be 62.4mM with
rateconstants,ka,of157/Ms,anddissociationrateconstants,
kd, of 9.76 10
 3/s (the chi-square value for the ﬁt is 2.39).
However, the binding constant and the dissociation constant
of PfClpQ–FI interaction suggest that the interaction has low
binding afﬁnity. A low signal/background ratio in the danys-
lated-peptide assays and low binding-peptide afﬁnity may be
responsible for high peptide concentration required in the
interaction studies (Figure 2).
To ascertain that the FI-peptide and PfClpY share the same
binding site on PfClpQ, solution-binding assays of Dansyl-FI-
peptide and PfClpQ were carried out in presence of PfClpY.
As shown in Figure 2f, presence of PfClpY in the assay
reduced binding of FI-peptide with PfClpQ. Level of inhibition
was a function of PfClpY concentration at a ﬁxed concentra-
tion of FI-peptide. However, when FI-peptide concentration
was increased, it was able to overcome this antagonism of
PfClpY and restored it’s binding with PfClpQ. These results
suggest that there is competition between FI-peptide and
PfClpY to bind with PfClpQ, and thus the FI-peptide shares
the PfClpQ-binding site with PfClpY protein. Further, we also
assessed the inhibition of PfClpY–PfClpQ binding in the
ELISA experiment by FI-peptide. Interaction of PfClpQ and
PfClpY was inhibited in presence of FI-peptide. The level
of inhibition was a function of FI-peptide concentration
(Figure 2g). However, as discussed above, a relatively high
concentration of FI-peptide is required to interfere with
PfClpQ–PfClpY interaction.
Effect of FI-peptide treatment on parasite growth. We
next investigated effect of FI-peptide on parasite growth
and development in vitro. To facilitate uptake of the peptide,
a 16-aa sequence of Antennapedia (Ant) homeoprotein
was coupled to the amino terminus of FI-peptide (Ant-FI)
(Supplementary Figure S5). The Antennapedia internaliza-
tion sequence has been known to facilitate uptake of
peptides into P. falciparum.
17,18 Treatment of parasite
cultures with Ant-FI-peptide inhibited parasite growth in a
dose dependent manner (Figure 3a). At 50mM concentration
Ant-FI-peptide showed B50% growth inhibition, and at
100mM it showed 90–95% growth inhibition (Figure 3a) as
compared with control. The effector concentration for half
maximum response (EC50) value was B50mM. No signi-
ﬁcant growth inhibition was observed in culture treated with
Ant-Scr control peptide (Figure 3a).
We also assessed any eventual recovery of FI-peptide
treated culture after removing the peptide at different time
points. Removal of the peptide at 1–3h after treatment
resulted in almost complete reversal of growth inhibition and
parasite cultures were able to recover; when peptide was
removed at 4h time point there was o20% growth inhibition
suggesting that about 80% of parasites were able to recover
the growth. However, when peptide was removed at 6h after
treatment, a large percentage of parasite (440%) population
was not able to recover (Supplementary Figure S6). Similarly
lower percentage population of parasite was able to recover
the growth when the peptide was removed at 8 or 16h after
treatment (Supplementary Figure S6).
Disruption of PfClpQY activity by FI-peptide disrupts the
intra-erythrocytic parasite cycle. To study the effect of
Ant-FI-peptide on parasite development and morphology,
synchronized parasite cultures at early-trophozoite stages
were treated with Ant-FI-peptide at 50mMo r9 0 mM
concentrations (BEC50 and BEC90 respectively). In control
sets, parasites developed from early-trophozoites to late-
trophozoites in 6–8h after treatment and subsequently into
mature schizonts within 12–16h after treatment. The
merozoites released from these schizonts invaded new
RBCs and developed into ring-stage parasites 24–30h
after treatment (Figure 3b). However, parasite treated
with Ant-FI-peptide showed abnormal developmental
morphology; in addition, these parasites were not able to
develop into schizonts. A large percentage of parasites in
cultures treated with Ant-FI-peptide showed condensed
cytosol, darkly stained nucleus and abnormal shape
of plasma membrane within 8–10h after treatment
(Figure 3c); later the parasite cytosol became completely
condensed and parasites appeared as densely stained
structures (Figure 3c). The percentage of parasites with
these ‘crisis form morphology’ increased with the incubation
time and peptide concentration. At 50mM, about 55%
of parasites showed crisis form morphology within 10–15h
after treatment, whereas at 90mM peptide concentration,
almost all parasites showed abnormal morphology and
turned into condensed round densely stained pycnotic
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Cell Death and Diseaseforms within 10–15h after treatment (Figure 3c). These
parasites remained as pycnotic forms in the culture and
did not show any vacuolated structure. These parasites
were not able to develop into schizonts or form any
merozoites (Figure 3b).
FI-peptide treatment disrupts mitochondria membrane
potential (Dwm). The morphological phenotypes induced
by FI-peptide treatment of parasites were reminiscent of
apoptosis phenotype. Therefore, we examined the treated
parasites for cellular features associated with the apoptosis.
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Figure 3 Effect of FI-peptide treatment on growth and development of P. falciparum.( a) Tightly synchronized early-trophozoite-stage parasite cultures (B30hpi) were
treated with different concentration of FI-peptide, Ant-FI peptide, Ant-scrambled peptide and solvent alone, percentage parasite growth was estimated by formation of new
ring-stage parasites as compared with untreated culture. (b) Effect of Ant-FI-peptide treatment (at 50 and 90mM) on parasite stage composition at different time points (30–
58hpi). The percentage of parasites at young trophozoite (YT), late trophozoite (LT), early schizont (ES), late schizont (LS), ring stage (R), and stressed pycnotic forms (Pyc)
are indicated. (c) Effect of Anti-FI-peptide treatment (at 90mM) on parasite morphology at different time points (30–58hpi)
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Cell Death and DiseaseGiven that the mitochondria is a key component of onset of
apoptosis and ClpQY machinery is functional in the parasite
mitochondria, we ﬁrst studied the effect of Ant-FI-peptide
treatment on mitochondria membrane potential by JC-1 dye
staining. In the control set, the parasites showed JC-1-red
stainingthatrepresentsJC-1aggregation inthemitochondria,
suggesting presence of functional mitochondria (Figure 4a).
The ratio of parasite population with mitochondrial red and
cytosolic green staining in the control set was found to be
B1.0 (Figure 4b). Parasite treated with Ant-FI-peptide at
BEC90 showed a signiﬁcant decrease in JC-1 red staining
after 3h (Figure 4a) leading to signiﬁcant decline in the ratio of
JC-1 red- and green-stained population to B0.4 (Figure 4b,
Supplementary Figure S7). Fluorescence microscopy also
showed loss of JC-1 red staining in the mitochondria of the
treated parasites (Figure 4c). These results clearly show loss
of mitochondria membrane potential (Dcm) in the parasite by
FI-peptide treatment. No or little effect was seen at 1h after
treatment of the parasites as evident from JC-1 red/green
ratio. Control parasite treated with solvent alone or with Ant-
scrambled peptide showed no signiﬁcant change in the
membrane potential (Figures 4a and b).
Loss of Dwm in FI-peptide treated parasites activates
caspase-like proteases and leads to apoptosis-like cell
death in parasite. We next assessed if loss of Dcm leads to
activation of any caspase-like cysteine protease activity in
the parasite. Synchronized parasite cultures were treated
with peptide or solvent alone, and analyzed at different time
points for staining with CaspACE (FITC–VAD–FMK), a cell
permeable and ﬂuorescent tagged in situ marker that binds
with activated caspase-like proteases. In solvent control sets,
a basal level of staining was detected in 5–10% of the
parasites. The Ant-FI-peptide (90mM) treated parasite
showed activation of caspase-like protease activity within
4h of treatment; the percentage of cell showing ﬂuorescent
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Figure 4 In situ mitochondrial membrane potential of P. falciparum parasite after treatment with Ant-FI-peptide as estimated by JC-1 staining. (a) Flow-cytometry
histogram showing reduction in JC-1 red staining in the parasite population treated with Ant-FI-peptide as compared with parasites treated with scrambled peptide or solvent
alone. (b) Graph showing ratio of JC-1 (red)/JC-1 (green) parasite population after treatment with Ant-FI, Ant-Scrambled (Ant-Scr) or solvent alone. (c) Fluorescent
microscopic images of JC-1-stainedparasite showing accumulation of aggregatedJC-1 (red staining) in the mitochondria and monomeric JC-1 (green staining) in the cytosol.
Treatment of Ant-FI-peptide caused loss of membrane potential, which reduced red staining in the mitochondria of the parasite. The parasite nuclei were stained with DAPI
(blue) and parasites were visualized by ﬂuorescence microscope
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Cell Death and Diseaselabeling increased for 4–12h after treatment reaching to a
maximum of B70% of parasites showing CaspACE staining
(Figures 5a and b and Supplementary Figure S8). However,
at time point earlier than 4h there was no signiﬁcant increase
in CaspACE-stained parasite population in the treated
cultures as compared with the control, suggesting that
activation of VAD–FMK-binding proteases occur B4h after
the treatment. At 16h after treatment, there was some
decrease in the number of stained parasites, which may be
due to increase in number of parasites in pycnotic crisis form
(Figures 5a and b and Supplementary Figure S8).
Further, we also analyzed the DNA fragmentation in the
parasites by using the TUNEL assay. The Ant-FI-peptide-
treated parasites showed TUNEL staining that overlapped
with the DAPI staining, (Figures 6a and b) suggesting
fragmentation of the nuclear DNA. The percentage of parasite
showing TUNEL staining increased as a function of peptide
concentration and time after treatment. Parasites treated with
peptide at BEC50 (50mM) showed TUNEL-positive cells 4h
after the treatment with maximum percentage of TUNEL-
positive parasites B50% at 16h after treatment. Whereas
cultures treated with peptide at BEC90 (90mM) showed
almost all the parasites (B90%) with TUNEL staining at 16h
after treatment (Figure 6a). Control parasite treated with
DMSO alone and parasite treated with Ant-scrambled peptide
did not show any TUNEL staining in the parallel assay.
Discussion
TheClpQY proteasemachinery consistsoftheClpQprotease
andanAAAþ chaperonClpY,whichtogetherformmultimeric
protein complex, presenting structural and functional analo-
gieswiththeeukaryotic26Sproteasome.Inthepresentstudy,
we have identiﬁed full ClpQY system in the malaria parasite.
Our results show that the ClpQ and ClpY protein in
P. falciparum are part of a protein complex as shown in
prokaryotes.
6–8 We have earlier carried out homology model-
ing and molecular docking studies of ClpQY protein complex,
these studies combined with computational alanine scanning
suggested mechanism of interaction between PfClpQ and
PfClpY subunits through the C-terminal residues of PfClpY in
the loop region.
19 To ascertain that the PfClpQ and PfClpY
interact directly to form a protein complex, we carried out
detailed in vitro and cell-based protein–protein interaction
studies. Our results show that the PfClpQ and PfClpY interact
with each other; the C-terminal region of PfClpY representing
the C-domain (PfClpY-C) is involved in its interaction with
PfClpQ and a short stretch of amino acids in the C terminus of
PfClpY has a key role in this interaction. These results
corroborated with our in silico interaction studies of the
PfClpQY protein complex.
19 With a view to understand the
functional role of ClpQY machinery in the parasite, we
identiﬁed a peptide-based inhibitor that could be utilized to
disrupttheinteractionofPfClpQandPfClpY,andhenceinhibit
function of ClpQY machinery in parasite. Small peptide-based
antagonists that are copy of natural motifs involved in
interactions of cognate proteins are being developed to
disrupt high-afﬁnity protein interactions and modulate target-
proteinmachineriesinthecells.
20–22Weassessedpotentialof
a synthetic peptide (FI-peptide), corresponding to the short
stretch at the C terminus of PfClpY, to bind with PfClpQ. The
FI-peptide showed speciﬁc binding with PfClpQ; competition-
binding assays showed that PfClpY and FI-peptide share the
same binding site on PfClpQ; further, the FI-peptide also
antagonizes PfClpQ and PfClpY interaction. These results
suggest that FI-peptide can be used to disrupt the ClpQY
functioning in parasites and study functional signiﬁcance of
this protease machinery. Recently, small peptides and
peptide-based inhibitors have been successfully used to
block function of different proteases and inhibit malaria
parasite growth.
17,18,23 The FI-peptide treatment caused
severe inhibition of parasite growth; further, development
of treated parasites was effected and these parasites
were not able to develop into mature schizonts. However,
micromolar concentrations of FI-peptide are needed to
exert the effect on parasite growth; this could be due to
slow uptake of peptides by parasites. Indeed, only high
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Figure 5 Activation of CaspACE–VAD–FMK binding cysteine proteases in
P. falciparum parasite. (a) Graph showing percentage of CaspACE-tagged
parasites in the cultures at different time points (4, 6, 8, and 16h) after treatment
with peptides Ant-FI, Ant-Scrambled (Ant-Scr) or solvent alone. (b) Flow cytometry
histogram showing population of CaspACE-tagged parasites in cultures 4h after
Ant-FI treatment as compared with controls
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Cell Death and Diseasemicromolar concentrations of peptide inhibitors are shown
to affect parasite growth in earlier studies.
17,18
The ClpQ protease was recently localized in the matrix of
themitochondriainP.falciparum;
23similarly,ClpQorthologue
was also localized in mitochondria of Trypanosoma brucei.
24
Parasite mitochondrion has an important role in critical
biosynthetic processes, including iron–sulfur cluster biosyn-
thesis, heme biosynthesis and ubiquinone biosynthesis.
25
As ClpQY is the only protease machinery localized in the
mitochondria, it may be having an important role in the
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Figure 6 DNA fragmentation in P. falciparum parasites as assessed by TUNEL staining. (a) Graph showing percentage of TUNEL-positive parasites in the cultures at
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Indeed, knocking down of ClpQ orthologue in T. brucei lead
to reduced growth of parasites.
24
The Plasmodium mitochondrion has a linear B6kb-long
genome that encodes three proteins, Cox1, CytB and Cox3,
as well as a number of rRNA subunits.
26,27 In addition, 4350
nuclear-encoded proteins are targeted to the parasite
mitochondrion.
28 These proteins have roles in different
metabolic pathways in the mitochondrion. Deregulation of
metabolic pathways in mitochondria and loss of mitochondrial
membrane potential is usually lethal for eukaryotic cells.
Inhibition of ATP-dependent Lon protease in mitochondria of
eukaryotic cells caused accumulation of aggregated proteins,
which subsequently lead to apoptosis of cells.
29 The ClpQY
system in parasite mitochondria might have an important
regulatory role for the parasite. Indeed, silencing of ClpQ in
T. brucei showed loss of control of replication of minicircle
DNAinthemitochondrialeadingtoreducedparasitegrowth.
24
Plasmodium mitochondrion does not possess minicircle DNA,
and the ClpQY machinery may be involved in regulation of
proteins involved in other metabolic pathways. Our results
withparasitegrowth-inhibitionassayusingFI-peptidesuggest
that the ClpQY protease machinery has an important
functional role in Plasmodium mitochondria; any interference
in its activity could destabilize the mitochondrial functioning.
Inhibition of ClpQY protease machinery using interfering FI-
peptide caused signiﬁcant loss of mitochondrial membrane
potential. This effect was combined with morphological
phenotypes of the parasites that are reminiscent of the
apoptosis-like phenotype, including condensation of cytosol
and darkly stained nucleus. Induction of apoptosis-like
features in asexual stage P. falciparum parasites is shown
after chloroquine treatment, which include cellular character-
istics, such as loss of mitochondrial membrane potential
(Dcm), activation of caspase-like cytseine proteases and
nuclear DNA fragmentation.
30,31 In the present study, disrup-
tion of ClpQY machinery also resulted in loss of Dcm, which
subsequently lead to increased number of CaspACE-tagged
parasites and DNA fragmentation of the parasites. These
results suggest that inhibition of the ClpQY machinery caused
deregulation of mitochondrial growth and functioning. Dys-
functioning of mitochondria in turn acts as an intrinsic signal in
the parasite, which initiates a cascade of reactions leading to
apoptosis-like cell death. We also assessed any eventual
recovery of the FI-peptide-treated culture after removing the
peptide at different time points; the FI-peptide treatment can
be reversed in early stage (1–4h), however longer treatment
induces changes in the parasite with point of no return.
We further show that activation of VAD–FMK-binding
proteases and DNA fragmentation follow after the loss of
Dcm in the parasite; loss in Dcm started at 2–3h after
treatment whereas caspase like-activity and DNA fragmenta-
tion were observed at 4–6h after treatment. The P. falciparum
genome does not contain any classical caspase-like protein.
Caspase-like activity is also described during apoptosis in
other organisms that lack classical caspases.
32–34 Although
P. falciparum genome also harbors two metacaspase-like
proteases that are closely related to eukaryotic caspases, it is
still not clear if these proteases are directly involved in
apoptosis-like process in parasites. Our results show that
VAD–FMK-binding proteases get activated after loss of
Dcm and dysfunctioning of the mitochondria. The identity of
VAD–FMK-binding proteases, exact role of these proteases,
speciﬁc target substrates and complex cascade of induction/
activation during apoptosis in parasites remains to be
elucidated.
Overall, we have identiﬁed the complete ClpQY machinery
in P. falciparum and show that the ClpQY machinery is
important for maintenance of functional mitochondria in
parasites. Our results suggest that deregulation of parasite
mitochondria triggers a cascade of reactions that leads to
apoptosis-like cell death in the parasite.
Materials and Methods
Parasite culture, and growth inhibition assays. P. falciparum strain
3D7 was cultured with human erythrocytes (4% hematocrit) in RPMI media
(Invitrogen,Eugene, OR, USA) supplemented with 10%Oþ humanserumusing a
protocol described previously.
35 Cultures were synchronized by repeated sorbitol
treatment, following Lambros and Vanderberg.
36 The amino-acid sequences of all
the peptides used in the study are given in Supplementary Table S1. Assays for
growth inhibition by different peptides were performed as previously described.
17
Brieﬂy, tightly synchronized P. falciparum 3D7 parasites at early-trophozoite stage
wereculturedin96-wellplatesinwhichhematocritandparasitemiawereadjustedto
4.0% and 0.8%, respectively. Puriﬁed peptides were added to the parasite cultures
to variable ﬁnal concentrations (1.0–125mM). Control wells were treated with
solvent alone. Each assay was performed in triplicate and the experiment was
repeated at least twice. The cultures were incubated for 24h, smears were made
fromeachwellatdifferenttimepointsandstainedwithGiemsa.Toassessgrowthof
the parasite, numbers of new ring-stage parasites formed were determined per
5000 RBCs, percentage parasitemia was calculated and percentage growth was
calculated as compared with the parasitemia in solvent controls. To assess any
recovery of the treated culture after peptide removal, the parasite cultures were
treated with the peptide at BEC50 as described above, subsequently the cultures
were washed with RPMI at different time points after treatment (1–16h) to remove
the peptide. Inhibition of parasite growth was assessed as described above and
compared with unwashed controls.
Isolation of DNA, total RNA and quantitative RT-PCR. The genomic
DNA was isolated from in vitro culture of P. falciparum following a standard
protocol.
37 Total RNAs were isolated from synchronized P. falciparum 3D7 parasite
cultures usingmini-RNAisolationkit (Qiagen, Hilden, Germany).Analiquotof 50ng
of total RNA was used to synthesize cDNA using cDNA synthesis kit (Invitrogen)
following manufacturer’s recommendations. Gene-speciﬁc primers were designed
using Beacon Designer4.0 software (Premier Biosoft, Palo Alto, CA, USA), for the
genes pfclpY (416A, 50-TTATATCCTCATGAGATTGTGGAATATTTG-30 and 461-
2A, 50-TTACCATGAAATCCAACTTCTGTAAAC-30), eba175 (EBA175RTF: 50-AAT
TTCTGTAAAATATTGTGACCATATG-30 and EBA175RTR: 50-GATACTGCACAAC
ACAGATTTCTTG-30) and falcipain 2 (Fal2F 50-GCTTGTAGGTTTTGGTATGAAAG
AA-30 and Fal2 R 50-AGATAGGTCCCTTTTTAAAATACTATTGAC-30);
38 18S rRNA
controlprimers(18SF50-GCTGACTACGTCCCTGCCC-30;18SR50-ACAATTCATC
ATATCTTTCAATCGGTA-30) were used following.
39 Quantitative real-time PCR
were carried out in triplicate using the iCycler version 3.0 (Bio-Rad); each reaction
was containing equal amount of cDNA, 100ng of each gene-speciﬁc primers and
1 SYBR Green PCR mix (Bio-Rad, Hercules, CA, USA). Threshold cycle (Ct)
values were calculated by using iCycler software. Standard curves for each gene
wereobtainedbyusingdifferentdilutionsofwild-typegDNA(100–1ng)astemplate,
andthesestandardcurveswereusedtodeterminegenomeequivalentsofCtvalues
for every gene and 18S rRNA in each RNA sample.
39 Genome equivalents of each
gene were normalized using that of 18S rRNA for all RNA samples.
Expression and puriﬁcation of recombinant proteins (PfClpQ,
PfClpY and C-terminal fragments of PfClpY) and ATPase
assay. Expression and puriﬁcation of recombinant protein corresponding to
mature region of PfClpQ (38–170 aa) was carried out as described earlier.
14
The threonine protease activity of puriﬁed-PfClpQ protein was assessed using
ﬂuorogenic-peptide substrate Z-GGL-AMC as described earlier.
14 A large fragment
of PfClpY (485–922 aa) harboring N-, I- and C-domains, was ampliﬁed from total
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TCATGAGATTGTGG-30 and415A,50-CCGAAGCTTCTCGAGTTATATGATATATT
TATTATAGTCGTATTGC-30. The ampliﬁed PCR product was digested with BamHI
and HindIII and cloned into BamHI and HindIII sites of pET28b vector (Novagen,
Merck Biosciences Ltd., Darmstadt, Germany). The recombinant plasmid pET28b-
PfClpY was transformed into Escherichia coli expression cells BL21(DE3)
(Novagen) for expression of recombinant protein with N-terminal histidine tag.
These cells were grown in Luria broth containing ampicillin (100mg/ml) at 371Ct o
an OD600nm of 0.5–0.6 and expression of the recombinantprotein was inducedwith
isopropyl-b-thioglactopyranoside (IPTG) at a ﬁnal concentration of 1.0mM. The
cultures were then allowed to grow for an additional 2h at 371C with shaking and
the E. coli cells were harvested by centrifugation. The cell pellet was suspended in
lysis buffer (20mM Tris pH 8.0, 250mM NaCl, 5mM benzamidine-HCl, 0.05%
Tween 20), lysed by sonication (Torebeo Ultrasonic Processor36800, Cole Parmer,
Vernon Hills, IL, USA) and centrifuged at 12000r.p.m. for 20min at 41C. The
inclusion-bodies pellet obtained was lysed in lysis buffer (10mM Tris-HCl, 100mM
NaCl, 6M Gu-HCl, 10mM Imidazole, pH 8.0) and the recombinant protein was
puriﬁed by afﬁnity chromatography using Ni-NTA resin. The protein was refolded
by rapid dilution in a buffer containing 50mM Tris-HCl buffer pH 7.4, 1mM EDTA,
1M urea, 2mM reduced glutathione, 0.2mM oxidized glutathione, 0.1mM PMSF
and 0.5M L-Arginine, keeping a ﬁnal protein concentration of o0.8mg/ml.
Subsequently, the sample was dialyzed against Tris-HCl buffer (pH 7.4) containing
20mM NaCl, and the recombinant protein was puriﬁed by an-ion exchange
chromatographyusingQ-Sepharoseresin.FractionscontainingpurePfClpYprotein
were pooled and concentrated.
A C-terminal fragment of PfClpY (725–922 aa) harboring the C-domains, was
ampliﬁed from total cDNA of the parasite by PCR using primers 601-2A, 50-GGC
GCCATGGAAGAAGGAATTGTTTTTATAG-30 and 570A, 50-GCCGGATCCTTATA
TGATATATTTTTTTAAGTCGTATTGC-30. The ampliﬁed fragment was cloned into
NcoI and BamHI sites of pET32b vector (Novagen) to give pET32-PfClpY-C
construct. A similar PfClpY fragment with 12-residue deletion at the C terminus
(725–910 aa; PfClpY-DC) was ampliﬁed using primers 601-2A, and 571A, 50-GCC
GGATCCTTAAATAAAACCTTCCAGCG-30, the ampliﬁed fragment was cloned
in pET32b vector to give pET32-PfClpY-DC. The recombinant PfClpY-C and
PfClpPY-DC proteins were expressed in E. coli cells harboring respective plasmid
construct. The recombinant proteins were puriﬁed from cytosolic fractions by
afﬁnity chromatography as described above using a column of Ni-NTA resin.
The hydrolysis of ATP by PfClpY was analyzed by pyrophosphate (
32P)-release
assay using g
32P-ATP. The reaction mixture consisting of labeled g
32P-ATP (9mCi)
and unlabeled ATP (1mM), 1–10mg of recombinant PfClpY protein in 20mM
Tris-HCl (pH 8.0) buffer containing 8mM DTT, 1.0mM MgCl2 and 10mM KCl
was incubated at 371C for 2h followed by thin-layer chromatography. The
chromatography plate was air dried and exposed to the X-ray ﬁlm.
Generation of polyclonal anti-sera and western immunoblotting.
To generate polyclonal anti-sera against PfClpY, female BALB/c mice were
immunized (on day 0) with the puriﬁed recombinant protein (25mg) formulated
in complete Freund’s adjuvant (Sigma, St. Louis, MO, USA). The mice were
administered two booster doses (day 14 and 28) of the proteins formulated in
Freund’s incomplete adjuvant. The mice serum was collected 10 days after the
second boost.
For western blot analyses, parasites were isolated from tightly synchronized
cultures at different developmental stages by lyses of infected erythrocyte with
0.15% saponin. Parasite pellets were washed with PBS, suspended in Laemmli
buffer, boiled, centrifuged, and the supernatant obtained was separated on 12%
SDS-PAGE. The fractionated proteins were transferred from gel onto the
nitrocellulose membrane (Amersham, Piscataway, NJ, USA) and blocked in
blocking buffer (1 PBS, 0.1% Tween-20, 5% milk powder) for 2h. The blot was
washed and incubated for 1h with primary antibody (mouse anti-PfClpY (1:500);
rabbit anti-PfClpQ (1:1000); rabbit anti-HRPII (1:2000)) diluted in dilution buffer
(1 PBS, 0.1% Tween-20, and 1% milk powder). Later, the blot was washed and
incubated for 1h with appropriate secondary antibody (anti-rabbit or anti-mouse,
1:2000) conjugated to HRP, diluted in dilution buffer. Bands were visualized by
using ECL detection kit (Amersham).
In vitro binding assays for protein–protein and protein–peptide
interactions. Protein–protein interaction was assessed by solution binding of
the two proteins followed by in vitro pulldown of the protein complex. Brieﬂy, anti-
PfClpY antibodies were allowed to bind with protein-A sepharose beads in 20mM
Tris pH 7.4, NaCl 150mM (TBS) for 30min at 41C with gentle agitation, the beads
werethen blocked with 5% BSA in TBS. RecombinantClpY andClpQ wereallowed
to bind with each other at 41C for 2h (ﬁnal concentration in the reaction 2mg/ml of
each) in the binding buffer. The mixture was then incubated (41C for 2h) with
protein A Sepharose beads having immobilized-anti-ClpY antibodies, to pull down
the complex. After extensive washing with TBS-T (TBS containing 0.1% Triton- X
100) the beads were boiled in SDS-PAGE buffer and centrifuged. The supernatant
was separated on SDS-PAGE, transferred to nitrocellulose and probed with anti-
PfClpQ antibodies. In control reactions, the ClpY protein was either absent or
replaced with a non-speciﬁc P. falciparum recombinant protein (MSP-119); in
another control the anti-ClpY antibodies were replaced with control antibodies
(pre-immune).
In vitro protein–protein interactions were also studied in an ELISA-based
assay. Brieﬂy, wells of Maxi-Sorp micro-titer plates (Nunc International, Nunc,
Langenselbold, Germany) were adsorbed with recombinant PfClpY (100ng in each
well) at 41C. The wells were washed thrice with 1 PBS containing 0.05% Tween-
20(PBS-T)andblockedwith1%BSAin1 PBSfor2h.PuriﬁedrecombinantClpQ
in varying concentrations (20–200ng) was added to the ClpY-coated wells and
incubated for 2h at room temperature. Plates were then washed ﬁve times with
PBS-T followed by sequential incubation with puriﬁed anti-ClpQ antibody (dilution
1:2000) and goat anti-mouse horse radish peroxidase (HRP)-labeled secondary
antibody (dilution 1:3000). After repeated washing, the enzyme reactions were
developed with 50mlo fo-phenylenediamine dihydrochloride-H2O2 in a citrate
phosphate buffer (pH 5.0), the reactions were stopped with 25mlo f2 NH 2SO4
and OD490 was measured using a 96-well micro-plate reader (Genios Pro; Tecan
Instruments, Tecan, Ma ¨nnedorf, Switzerland).
Solution-bindingassayswerecarriedout tostudy interaction of ClpQproteinand
peptides following Ramachandran et al.
40 The dansylated FI-peptide (Dansyl-
FIKQYDLKKYII) was added to varying ﬁnal concentration (10–100mM) in wells of a
ﬂat-bottom micro-titer plate containing 200ml protein ClpQ (monomeric concentra-
tion of 13mM) in 20mM Tris, 300mM NaCl. The ﬂuorescence spectra from each
well were recorded at emission and excitation wavelengths of 335 and 533nm,
respectively, using Fluo-Star micro-plate reader (BMG Technologies, BMG
LABTECH, Ortenberg, Germany). Enhancement in ﬂuorescence values (DF533)
were calculated after subtracting values from respective control wells where the
dansylated peptide was added only to the buffer. For competition assay between
dansylated and unlabeled FI peptide, increasing concentrations (10–70mM) of un-
labeled peptide (FIKQYDLKKYII) were added to the wells containing ClpQ and
80mM of dansylated peptide for the same assay. To assess the competition
between FI-peptide and ClpY for binding with recombinant ClpQ, the solution-
binding assays were carried out in the same way using dansylated FI-peptide in
presence of varied concentrations of ClpY protein.
Surface-plasmon resonance analysis. Real-time interactions of
PfClpQ with FI-peptide (FIKQYDLKKYII) were analyzed by surface plasmon
resonance studies under ﬂow condition using Biacore 2000 instrument.
The carboxymethylated-dextran surfaces of Biacore CM5 sensor chips were
activated by injection of 1:1 mixture of N-hydroxysuccinimide (NHS) (Biacore AB,
Biacore, Uppsala, Sweden) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide
hydrochloride(EDC)(BiacoreAB)for7min ataﬂow rateof10ml/min.Recombinant
PfClpQ (10mg/ml in 10mM sodium acetate buffer, pH 4.5) was injected over the
activated surface of a sensor chip ﬂow cell at a ﬂow rate of 10ml/min so as to
achievean immobilization equivalentto 500RU.A non-speciﬁcrecombinantprotein
was immobilized on surface of another sensor chip ﬂow cell in similar way and was
used as a negative control. A third sensor chip ﬂow cell was blocked by injection of
ethanolamine (Biacore AB) at a ﬂow rate of 10ml/min for 5min and was used as
blank. Kinetic-binding analysis for interaction of PfClpQ was carried out by injecting
the FI-peptide at different concentrations (5, 10, 20, 40mM) in independent
experiments. The peptide or recombinant proteins were injected for 4min at a ﬂow
rate of 30ml/min with the running buffer (10mM HEPES, pH 7.4, 150mM NaCl,
3mM EDTA and 0.005% P20 surfactant); the dissociation was monitored for 240
seconds with the running buffer at the same ﬂow rate. To correct for refractive index
changescausedbyrunningbufferandinstrumentnoise,runningbufferwasinjected
at a ﬂow rate of 30ml/min in the blank ﬂow cells and the observed response
difference was subtracted from the experimental data. The ﬂow rate of the peptide
and the recombinant proteins was varied from 10 to 75ml/min in order to assess
whether the binding interactions were limited by mass transfer. A non-speciﬁc
peptide (Ant peptide) was used in the control experiments. The experimental
surface was regenerated by injecting regeneration solution (1M ethanolamine) at a
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Cell Death and Diseaseﬂowrateof30ml/minfor1min.Thebindingconstant,Kd,wascalculatedaskd1/ka1
by using data analysis program BIAevaluation 3.2RC1 (Biacore AB). Kinetic rate
constants were determined by ﬁtting the corrected response data to a simple 1:1
(Hill–Langmuir binding isotherm model using BIAevaluation 3.2RC1 software).
Co-immunoprecipitation of PfClpQY complex in the parasite
lysate. Infected RBCs were collected from synchronized parasite culture
(late-trophozoite stage), suspended in 1 PBS pH 7.4 containing cleavable
protein cross-linker DTSSP (Pierce Biotechnology Inc., Rockford, IL, USA) (ﬁnal
concentration 2mM) and incubated for 2h on ice. The parasites were harvested by
lysis of the infected RBCs by 0.15 % saponin in RPMI for 10min on ice. Parasite
pellet was suspended in TEN buffer (Tris 50mM pH 7.4, 20mM EDTA) containing
protease-inhibitor cocktail (Roche, Indianapolis, IN, USA) and then lysed by three
freeze-thaw cycles. The lysate was clariﬁed by centrifugation at 12000 g for
30min at 41C and pre-cleared with Protein-A Sepharose beads. The pre-cleared
parasiteextract was incubatedwith Protein-ASepharosebeadshaving immobilized
anti-PfClpY antibodies(anti-PfClpY-ProteinA Sepharosebeads) for 2h at 41C with
gentle agitation. After incubation the beads were washed extensively in TEN buffer
containing 0.1% Tween-20. The immune complex were dissociated by boiling the
beadsinSDS-PAGEbufferandcentrifugedtoseparatethebeads.Thesupernatant
was separated on SDS-PAGE and analyzed by immunoblotting using anti-PfClpQ
antibodies. In control reactions, the anti-PfClpY antibodies were replaced with
control antibodies (pre-immune) or with antibodies against a non-speciﬁc P.
falciparum protein, PfAARP.
41
Mitochondria membrane potential assay. The mitochondrial membrane
potential was assessed in the parasite using MitoProbe JC-1 Assay Kit for Flow
Cytometry (Molecular Probe, Eugene, OR, USA), this kit uses a unique cationic dye,
JC-1 (5,50,6,60-tetrachloro-1,10,3,30- tetraethylbenzimidazolylcarbocyanine iodide),
that remains in monomeric form in the cytoplasm and has a green ﬂuorescence
(525nm). However, the membrane potential of functional mitochondria establishes a
negative charge that allows the lipophilic dye to accumulate and form aggregates in
the mitochondria, which have red ﬂuorescence (590nm). Infected RBCs were
collected from parasite cultures in control and experimental sets at different time
points and incubated with JC-1 dye (at a ﬁnal concentration. of 10mM) for 30min at
371C. Cells were washed with PBS and analyzed by ﬂow cytometry using
FACSCalibur ﬂow cytometer and CellQuestPro software (Becton Dickinson,
San Jose, CA, USA). The infected RBCs were analyzed using green (488nm) and
red (635nm) ﬁlters. Ratio of JC-1 (red)/JC-1 (green) were calculated to assess the
loss of mitochondrial membrane potential. The JC-1-stained uninfected RBCs were
used as background controls.
Caspase-likecysteineprotease-activationassay. A speciﬁccaspase-
inhibitorCaspACEFITC–VAD–FMKInSituMarker(Promega,Mannheim,Germany)
was used to assess activation of Caspase-like cysteine protease activity in the
parasite, following manufacturer’s instructions. Brieﬂy, the infected RBCs were
collected from parasite cultures in control and experimental sets at different time
points and incubated with 10mM of CaspACE FITC–VAD–FMK for 30min at 371C
followed by washing with 1 PBS. The stained samples were analyzed by ﬂow
cytometer using FACSCalibur ﬂow cytometer and CellQuestPro software (Becton
Dickinson) to assess ﬂuorescence staining of infected RBCs.Uninfected RBCswere
used as background control and parasite culture treated with solvent alone was
used as negative controls.
Terminal deexynucleotidyl transferase (TdT) mediated dUTP
nick-end labeling (TUNEL). The DNA fragmentation in the parasite was
assessed by TUNEL using In Situ Cell Death Detection Kit, TMR Red (Roche
Applied Science), following manufacturer’s instructions. Brieﬂy, the infected RBCs
fromcontrolandexperimentalwellswerecollectedatdifferenttimepoints,ﬁxedwith
4% paraformaldehyde (PFA) for 1h and washed with 1 PBS. Subsequently, the
cells were incubated with a mixture of TdT enzyme and TMR Red-labeled dUTP for 1h
at 371C. The labeled parasites were observed under ﬂuorescence microscope
and percentage of TUNEL-positive parasites was calculated. Untreated parasites
and parasites treated with DNase were used as negative and positive controls,
respectively.
Fluorescence microscopy. P. falciparum cultures stained with JC-1 dye
and by TUNEL assay were visualized by ﬂuorescence microscopy. These parasites
werestainedwith DAPIat a ﬁnalconcentrationof 2mg/mlfor 30min at371C before
imaging. The stained parasites were viewed using a Nikon TE 2000-U ﬂuorescence
microscope or Nikon A1R confocal laser scanning microscope (Nikon, Tokyo,
Japan). For TUNEL assay, total number of parasites was counted by nuclear
staining and percentage of TUNEL-positive parasites was calculated. To study
uptake of peptide in the parasite, the peptide was labeled with EZ-Link Sulfo-NHS-
LC-LC-Biotin(Pierce)followingmanufacturer’sinstruction;thetreatedparasitewere
ﬁxed in 4% PFA, stained with streptavidin-FITC and MitoTracker Red CMXRos
(Invitrogen) as described earlier
15 and the parasite was visualized using
ﬂuorescence microscope.
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